Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Konrad Lewandowski
Institutions:
Poznan University of Medical Sciences,
National Medical Institute of the Ministry of Interior and Administration
Observed institutions:
Poznan University of Medical Sciences,
National Medical Institute of the Ministry of Interior and Administration
ORCID:
0009-0001-3029-5992
Observed ORCID:
0009-0001-3029-5992
OpenAlex ID:
A5018631474
Photosensitizers Mediated Photodynamic Inactivation against Fungi
2021
·
Daniel Ziental
, Dariusz T. Mlynarczyk
, et al.
·
Nanomaterials
·
59
PDF
Oxospirochlorins as new promising photosensitizers against priority pathogens
2022
·
Daniel Ziental
, Justyna Zajac
, et al.
·
Dyes and Pigments
·
10
PDF
Pharmacokinetic interaction between regorafenib and atorvastatin in rats
2024
·
Danuta Szkutnik-Fiedler
, Edyta Szałek
, et al.
·
Pharmacological Reports
·
7
PDF
A comprehensive review of usefulness of sodium butyrate for the management of inflammatory bowel disease: from molecular mechanisms to clinical application
2026
·
Katarzyna Karłowicz
, Konrad Lewandowski
, et al.
·
Gastroenterology Review
·
6
PDF
Bioanalytical method validation for therapeutic drug monitoring of olaparib in patients with ovarian cancer
2024
·
Konrad Lewandowski
, Agnieszka Karbownik
, et al.
·
Acta Poloniae Pharmaceutica - Drug Research
·
3
PDF
Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis
2026
·
Łukasz Lamparski
, Katarzyna Karłowicz
, et al.
·
Gastroenterology Review
·
2
PDF
Fecal butyric acid as a predictive biomarker of endoscopic remission in inflammatory bowel disease: a multicenter prospective study
2025
·
Katarzyna Karłowicz
, Konrad Lewandowski
, et al.
·
Gastroenterology Review
·
2
PDF
Drug-related problems in hospitalized oncology patients, with special focus on radiotherapy units: Implications for oncology pharmacy practice
2026
·
Katarzyna Regulska
, Marcin Michalak
, et al.
·
Journal of Oncology Pharmacy Practice
·
1
Development of a UPLC-MS/MS method and its application for the pharmacokinetic analysis of regorafenib in rats
2026
·
Filip Otto
, Viktoriia Propisnova
, et al.
·
Scientific Reports
·
1
RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients
2026
·
Konrad Lewandowski
, Katarzyna Karłowicz
, et al.
·
Gastroenterology Review
·
1
PDF
Analysis of niraparib-induced changes in glucose levels during three-month therapy in normoglycemic patients with ovarian cancer.
2025
·
Joanna Stanislawiak-Rudowicz
, Edyta Szalek
, et al.
·
Journal of Clinical Oncology
·
1
Metastatic Crohn’s disease as a granulomatous bridge between gastroenterology, rheumatology and dermatology
2026
·
Raman Nitskovich
, Konrad Lewandowski
, et al.
·
Reumatologia/Rheumatology
PDF
Assessment of Potential Drug-Drug Interactions Among Patients With Ovarian Cancer Receiving Olaparib
2026
·
Joanna Stanisławiak-Rudowicz
, Edyta Szalek
, et al.
·
Acta Poloniae Pharmaceutica - Drug Research
PDF
Niraparib induces hyperglycemia in ovarian cancer patients: a preliminary pilot study
2025
·
Konrad Lewandowski
, Joanna Stanisławiak-Rudowicz
, et al.
·
Pharmacological Reports
PDF
Show more works
View as search
Works count:
14
Citation count:
93
H-index:
4
I10-index:
2
Year
Topic
Type